Replimune Group (REPL) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.54

Estimate

-$0.79

Surprise

+31.5%

Score today

5.1/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Replimune Group (REPL) reported a narrower loss than forecast — adjusted EPS of -$0.54 against the -$0.79 estimate (a 31.5% beat on a still-unprofitable quarter).

• Replimune Reports Fiscal Second Quarter 2027 Financial Results — fiscal.ai, 2026-10-28
• Replimune Group Q2 2027 Earnings Call Transcript — benzinga, 2026-10-28
• Replimune Group Q2 EPS $(0.54) Beats $(0.77) Estimate — benzinga, 2026-10-28

TrendMatrix currently rates REPL Sell at 5.1/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's +31.5% surprise compares with a +10.7% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$16.06

Price target

$16.96

Stop

$14.94

Upside to target

+5.6%

Reward-to-risk

0.4:1

Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.51B

P/E (fwd)

-8.8

52-week range

$1.50–$16.75

Off 52-week high

4.1%

RSI (14)

65

Volume vs avg

3.27×

Score today

5.1/10